Merus N.V. (MRUS)’s Financial Results Comparing With Axsome Therapeutics Inc. (NASDAQ:AXSM)

As Biotechnology businesses, Merus N.V. (NASDAQ:MRUS) and Axsome Therapeutics Inc. (NASDAQ:AXSM), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Merus N.V. N/A 0.00 N/A -2.03 0.00
Axsome Therapeutics Inc. N/A 0.00 30.97M -1.13 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Merus N.V. and Axsome Therapeutics Inc.


Table 2 shows us Merus N.V. and Axsome Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Merus N.V. 0.00% -46% -17.1%
Axsome Therapeutics Inc. 0.00% -310.9% -113.7%


The Current Ratio and a Quick Ratio of Merus N.V. are 5.3 and 5.3. Competitively, Axsome Therapeutics Inc. has 1.5 and 1.5 for Current and Quick Ratio. Merus N.V.’s better ability to pay short and long-term obligations than Axsome Therapeutics Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Merus N.V. and Axsome Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Merus N.V. 0 1 2 2.67
Axsome Therapeutics Inc. 0 0 2 3.00

Merus N.V.’s average target price is $21.33, while its potential upside is 57.30%. Competitively Axsome Therapeutics Inc. has a consensus target price of $25, with potential upside of 73.61%. The information presented earlier suggests that Axsome Therapeutics Inc. looks more robust than Merus N.V. as far as analyst belief.

Insider & Institutional Ownership

Institutional investors held 68.9% of Merus N.V. shares and 12.9% of Axsome Therapeutics Inc. shares. About 31.46% of Merus N.V.’s share are held by insiders. Comparatively, insiders own roughly 30.4% of Axsome Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Merus N.V. 15.68% 6.03% 0.71% -35.51% -28.39% -8.29%
Axsome Therapeutics Inc. -12.24% -3.46% 154.72% 145.45% 217.65% 187.23%

For the past year Merus N.V. had bearish trend while Axsome Therapeutics Inc. had bullish trend.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.